Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Fennec Pharmaceuticals Inc. Common Stock (FENC)

Biological Products, (no Disgnostic Substances)

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

PO BOX 13628, 68 TW ALEXANDER DRIVE
RESEARCH TRIANGLE PARK, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/28/2002

Market Cap

153,787,366

Shares Outstanding

26,640,000

Weighted SO

26,709,469

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

MOLN --.--%

MNOV --.--%

ANEB --.--%

CSBR --.--%

CYT --.--%

KROS --.--%

JANX --.--%

EWTX --.--%

HRMY --.--%

Beta

0.2900

Last Div

0.0000

Range

5.26-11.92

Chg

0.0400

Avg Vol

110140

Mkt Cap

153787366

Exch

NASDAQ

Country

US

Phone

919 636 4530

DCF Diff

9.1451

DCF

-3.5351

Div Yield

0.0000

P/S

3.1358

EV Multiple

23.9745

P/FV

-113.0669

Div Yield %

0.0000

P/E

57.6288

PEG

1.6102

Payout

0.0000

Current Ratio

8.0232

Quick Ratio

7.7465

Cash Ratio

5.5561

DSO

91.6176

DIO

357.2239

Op Cycle

448.8415

DPO

740.9398

CCC

-292.0982

Gross Margin

0.9553

Op Margin

0.1174

Pretax Margin

0.0531

Net Margin

0.0543

Eff Tax Rate

0.0515

ROA

0.0422

ROE

-0.5210

ROCE

0.1039

NI/EBT

1.0220

EBT/EBIT

0.4523

EBIT/Rev

0.1174

Debt Ratio

0.4713

D/E

-21.9344

LT Debt/Cap

1.0478

Total Debt/Cap

1.0478

Int Coverage

3.2700

CF/Debt

0.7771

Equity Multi

-46.5446

Rec Turnover

3.9840

Pay Turnover

0.4926

Inv Turnover

1.0218

FA Turnover

0.0000

Asset Turnover

0.7766

OCF/Share

0.8472

FCF/Share

0.8472

Cash/Share

1.5770

OCF/Sales

0.4716

FCF/OCF

1.0000

CF Coverage

0.7771

ST Coverage

1927.5427

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

-113.0669

P/B

-113.0669

P/S

3.1358

P/E

57.6288

P/FCF

6.6498

P/OCF

6.6334

P/CF

6.6334

PEG

1.6102

P/S

3.1358

EV Multiple

23.9745

P/FV

-113.0669

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 05, 05:55 Fennec Announces Incremental $5 Million Investment from Petrichor GlobeNewswire Inc. Nov 09, 16:50 Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire Inc. Oct 30, 06:45 Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Revenue Product Segmentation